Literature DB >> 24004672

Better performance of CARs deprived of the PD-1 brake.

Aizea Morales-Kastresana1, Sara Labiano, José I Quetglas, Ignacio Melero.   

Abstract

Immunotherapies often permit combinations to increase efficacy. Two approaches are currently leading our field: adoptive therapy with T cells transfected with chimeric antigen receptors and monoclonal antibodies blocking the PD-1/PD-L1 (B7-H1) axis. In this issue of Clinical Cancer Research, preclinical evidence for a synergistic combination of such approaches is reported. ©2013 AACR.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24004672     DOI： 10.1158/1078-0432.CCR-13-2157

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  5 in total

Review 1.  Emerging Opportunities and Challenges in Cancer Immunotherapy.

Authors:  Theresa L Whiteside; Sandra Demaria; Maria E Rodriguez-Ruiz; Hassane M Zarour; Ignacio Melero
Journal:  Clin Cancer Res       Date:  2016-04-15       Impact factor: 12.531

2.  Impact of a New Fusion Receptor on PD-1-Mediated Immunosuppression in Adoptive T Cell Therapy.

Authors:  Sebastian Kobold; Simon Grassmann; Michael Chaloupka; Christopher Lampert; Susanne Wenk; Fabian Kraus; Moritz Rapp; Peter Düwell; Yi Zeng; Jan C Schmollinger; Max Schnurr; Stefan Endres; Simon Rothenfußer
Journal:  J Natl Cancer Inst       Date:  2015-06-23       Impact factor: 13.506

3.  Genetic modification of T cells redirected toward CS1 enhances eradication of myeloma cells.

Authors:  Jianhong Chu; Shun He; Youcai Deng; Jianying Zhang; Yong Peng; Tiffany Hughes; Ling Yi; Chang-Hyuk Kwon; Qi-En Wang; Steven M Devine; Xiaoming He; Xue-Feng Bai; Craig C Hofmeister; Jianhua Yu
Journal:  Clin Cancer Res       Date:  2014-03-27       Impact factor: 12.531

Review 4.  Evolving synergistic combinations of targeted immunotherapies to combat cancer.

Authors:  Ignacio Melero; David M Berman; M Angela Aznar; Alan J Korman; José Luis Pérez Gracia; John Haanen
Journal:  Nat Rev Cancer       Date:  2015-08       Impact factor: 60.716

5.  Adoptive transfer of murine T cells expressing a chimeric-PD1-Dap10 receptor as an immunotherapy for lymphoma.

Authors:  Adam Lynch; William Hawk; Emily Nylen; Sean Ober; Pierre Autin; Amorette Barber
Journal:  Immunology       Date:  2017-07-27       Impact factor: 7.397
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.